^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMB302

    i
    Other names: AMB302, GR1017, GQ1011, AMB 302, GQ 1011, GR 1017, AMB-302, GQ-1011, GR-1017
    Company:
    Aimed Bio, GeneQuantum Healthcare
    Drug class:
    Topoisomerase I inhibitor, FGFR3-targeted antibody-drug conjugate
    Related drugs:
    almost2years
    AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion (AACR 2023)
    AMB302/GR1017 showed robust anti-tumor efficacies in F3-T3 fusion and FGFR3 overexpression models derived from GBM and BC in vitro and in vivo. In addition, AMB302/GR1017 was well tolerated with no adverse effects in rodent model. Our data suggest AMB302/GR1017 has a potential therapeutic option as a first-in-class FGFR3 targeting ADC for GBM, BC, and other solid tumors with FGFR3 overexpression or alterations.
    Preclinical
    |
    FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
    |
    FGFR3-TACC3 fusion • FGFR3 overexpression • FGFR3 fusion • FGFR3 amplification • FGF3 overexpression
    |
    AMB302